The IMPOWER-LUNG 1, a phase 3 randomized controlled trial, evaluated patients with advanced NSCLC without EFGR/ALK/ROS1 alterations and with PD-L1 ≥ 50%. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.